Equity Components [Axis] Common Stock [Member] Common Stock Purchase Warrant [Member] Class of Stock [Axis] Series A Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Series C-1 Convertible Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Preferred Stock [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Antidilutive Securities [Axis] Convertible Debt Securities [Member] Share-Based Payment Arrangement, Option [Member] Warrant [Member] Business Combination [Axis] Phytanix Bio Inc [Member] Series C Preferred Stock [Member] Series C-1 Preferred Stock [Member] Series D Preferred Stock [Member] Investment, Name [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Unwind Agreement [Member] Intangible Asset, Finite-Lived, Class [Axis] In Process Research and Development [Member] Assembled Workforce [Member] Phytanix Bio [Member] Award Type [Axis] Title and Position [Axis] President [Member] Employees [Member] Non-Employees [Member] Research Agreements [Member] Licensing Agreements [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Listing, Par Value Per Share ASSETS Current assets: Cash in bank Prepaid expenses Total current assets Long-term assets: Fixed assets, net Intangible assets, net Total long-term assets Total Assets LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) LIABILITIES: Current liabilities: Accounts payable Accrued liabilities Total current liabilities Total liabilities Commitments and Contingencies - NOTE 12 STOCKHOLDERS’ EQUITY: Preferred stock, value Common stock, $0.0001 par value, respectively; 100,000,000 authorized; 1,810,208 and 1,810,208 shares issued outstanding Additional paid in capital Accumulated deficit Foreign currency translation adjustment Total stockholders’ equity Total liabilities and stockholders’ equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] OPERATING EXPENSES: Accounting and audit fees Research and Development Legal Fees Consulting Fees Salaries and wages General and administrative - other Stock compensation TOTAL OPERATING EXPENSES LOSS FROM OPERATIONS OTHER EXPENSES: Interest income (expense) Derivative expense Change in fair value of derivative liabilities Foreign currency exchange differences Impairment of intangible assets Gain/loss on extinguishment of debt TOTAL OTHER EXPENSES LOSS BEFORE INCOME TAXES PROVISION FOR INCOME TAXES NET LOSS NET LOSS PER SHARE: Basic Diluted WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: Basic Diluted COMPREHENSIVE LOSS: Net loss Other comprehensive gain (loss): Unrealized foreign currency translation gain (loss) Comprehensive loss Balances Balance, shares Change in foreign currency Issuance of Series A Convertible Preferred Stock to officers Issuance of Series A Convertible Preferred Stock to officers, shares Adjustment of shares in reverse merger Adjustment of shares in reverse merger, shares Shares issued in connection with Phytanix Bio purchase Shares issued in connection with Phytanix Bio purchase, shares Shares issued for cash Shares issued for cash, shares Shares issued for warrant exercises Shares issued for warrant exercises, shares Shares issued for option exercises Stock-based compensation Rounding from reverse split Rounding from reverse split, shares Net income (loss) Balances Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net income/loss to net cash flows used in operating activities: Amortization of debt discount to interest expense Stock based compensation Derivative expense Change in fair value of derivative liabilities Depreciation expense Impairment of intangible assets Changes in operating assets and liabilities: Inventories Prepaid expenses VAT receivable Accounts payable Accrued liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Cash received in acquisition of Phytanix Bio Net cash provided by investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Increase in note payable for acquisition of Phytanix Bio Net proceeds from notes payable Proceeds from sale of common stock Proceeds from exercise of warrants Proceeds from related party loans Net cash provided by financing activities NET INCREASE IN CASH Effect of exchange rate adjustments on cash CASH, beginning of period CASH, end of period SUPPLEMENTAL SCHEDULE OF CASH FLOW INFORMATION: Interest paid Income taxes paid NON-CASH INVESTING AND FINANCING INFORMATION: Net assets acquired of Phytanix Bio, net of cash paid Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND NATURE OF BUSINESS LIQUIDITY AND GOING CONCERN Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] REVERSE MERGER Property, Plant, and Equipment [Abstract] FIXED ASSETS Intangible Asset, Goodwill and Other [Abstract] INTANGIBLE ASSETS Payables and Accruals [Abstract] ACCOUNTS PAYABLE ACCRUED LIABILITIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Equity [Abstract] STOCKHOLDERS’ EQUITY COLLABORATIVE AGREEMENTS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Segment Reporting [Abstract] SEGMENT REPORTING Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of presentation Principles of consolidation Use of estimates Concentrations of Credit Risk Cash and Cash Equivalents Fixed Assets and Long-Lived Assets Fair Value Measurements Derivative Financial Instruments Income Taxes Research and development Segment Reporting Stock-Based Compensation Basic and Diluted Net Income (Loss) per Common Share Foreign Currency Translation Recent Accounting Pronouncements SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE SCHEDULE OF PURCHASE PRICE ALLOCATION SCHEDULE OF BUSINESS COMBINATION CONTINGENT CONSIDERATION SCHEDULE OF FIXED ASSETS SCHEDULE OF INTANGIBLE ASSETS SCHEDULE OF ACCOUNTS PAYABLE SCHEDULE OF ACCRUED LIABILITIES SCHEDULE OF FAIR VALUE OF EACH OPTION GRANTED SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES SUMMARY OF WARRANT Description of reverse stock split Gain/loss on extinguishment of debt Bad debt expense Working capital deficit Accumulated deficit Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total potentially outstanding dilutive common shares Cash equivalents Cash Impairment of long-lived assets Current assets – cash and prepaid Intangible assets – in process research and development and assembled workforce Fixed assets Accounts payable and accrued expenses Purchase price Cash Receipt of Company shares Total Consideration Total Assets of Phytanix Less: Total Liabilities of Phytanix Net Liabilities Deconsolidated Less: Net Assets Deconsolidated Gain on disposal of subsidiary Business Combination [Table] Business Combination [Line Items] Shares issued Equity interests in acquiree, percentage Warrants purchased Outstanding capital stock of Phytanix Bio. Debt securities current Debt securities non current Gain on disposal of subsidiary Equipment Accumulated depreciation Net fixed assets Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Line Items] Intangible assets, gross Accumulated amortization Net intangible assets Accounting and audit fees Research and development Legal General and administrative Total accounts payable Research and development General and administrative Total accrued expenses Exercise price Expected dividend yield Risk free interest rate Expected life in years Expected volatility Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of Stock Options Outstanding, Beginning Weighted Average Exercise Price, Beginning Weighted Average Remaining Life, Outstanding Number of Stock Options, Granted Weighted Average Exercise Price, Granted Weighted Average Remaining Life, Granted Number of Stock Options, Expired Weighted Average Exercise Price, Expired Number of Stock Options, Exercised Weighted Average Exercise Price, Exercised Number of Stock Options Outstanding, Ending Weighted Average Exercise Price, Ending Nonvested Options, Balance Weighted-Average Exercise Price, Balance Nonvested Options, Granted Weighted-Average Exercise Price, Granted Nonvested Options, Vested Weighted-Average Exercise Price, Vested Weighted-Average Exercise Price, Forfeited Weighted-Average Exercise Price, Forfeited Nonvested Options, Balance Weighted-Average Exercise Price, Balance Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Number of Warrants Outstanding, Beginning Weighted Average Exercise Price, Outstanding, Beginning Weighted Average Remaining Life Outstanding Number of Warrants, Granted Weighted Average Exercise Price, Granted Number of Warrants, Expired Weighted Average Exercise Price, Expired Number of Warrants, Exercised Weighted Average Exercise Price, Exercised Number of Warrants Outstanding, Ending Weighted Average Exercise Price, Outstanding, Ending Number of shares issued in merger Number of shares issued for cash Value of shares issued for cash Common stock issued in exercise of warrants Value of common stock issued in exercise of warrants Number of reverse split shares Common stock issuable upon conversion Conversion price Preferred stock, stated value Number of options outstanding Number of stock options issued weighted average exercise price of options outstanding Intrinsic value of options outstanding Exercise price of options issued Options vesting period Options expiration period Stock-based compensation Unamortized stock option expense Weighted average vesting period for unamortized stock compensation Shares issuable under warrants outstanding Warrant exercise price Warrants outstanding, intrinsic value Stock-based compensation expense Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Research and development expense Royalty payment, percentage Up-front sub-license fees, percentage Royalty payment on behalf of sublicensee percentage Sales revenue Minimum bid price Reverse stock split description Number of operating segments Number of reportable segments Common Stock Purchase Warrant [Member] Cash in bank Working Capital Deficit. Accrued research and development. Series A Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Phytanix Bio [Member] Series C-1 Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Series C-1 Convertible Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Preferred stock stated value. Accounting and Audit Fees. Derivative Gain Loss On Derivative Net and Fair Value Adjustment of Warrants. Foreign Currency Exchange Differences. Phytanix Bio Inc [Member] Unwind Agreement [Member] Stock issued during period value Preferred Stock to Officers. Stock issued during period shares preferred stock to officers. Consideration of cash Receipt of company shares Stock issued during period value reverse merger. Stock issued during period shares reverse merger. Business combination separately recognized transactions assets. Business combination separately recognized transactions liabilities net liabilities deconsolidated. Business combination separately recognized transactions liabilities net deconsolidated. Stock issued during period value Bio Purchase. Stock issued during period shares Bio Purchase. Business combination separately recognized transactions net gain and losses. Stock issued during period value warrant exercise. Stock Issued During Period Shares Warrant Exercise. Stock issued during period value option exercise. Rounding from reverse split. Rounding from reverse split shares. Research and development current. Legal current. General and administrative current. Sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual granted. Increase decrease in value added tax receivable. Increase in note payable for acquisition of phytanix bio. Net assets acquired of Phytanix Bio net of cash received. Employees [Member] Non-Employees [Member] Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan. Share based payment award non option equity instruments outstanding weighted average remaining contractual term. Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity. Number of warrants outstanding, weighted average exercise price, expired. Number of warrants outstanding, weighted average exercise price, expired Class of warrant or right, outstanding, intrinsic value. Research Agreements [Member] The percentage of royalty payment of net sales. The percentage of royalty payment of net sales made on behalf of a sub-licensee. Assembled Workforce [Member] Up-front sub-license fees, percentage. Assets, Current Assets, Noncurrent Assets Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Diluted Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense IncreaseDecreaseInValueAddedTaxReceivable Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Payments for (Proceeds from) Previous Acquisition Cash Provided by (Used in) Investing Activity, Including Discontinued Operation IncreaseInNotePayableForAcquisitionOfPhytanixBio Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Business Combination, Recognized Liability Assumed, Accounts Payable, Current Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill ConsiderationOfCash Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization Intangible Asset, Finite-Lived, Accumulated Amortization Accrued Professional Fees, Current ResearchAndDevelopmentCurrent AccruedResearchAndDevelopment Other Accrued Liabilities, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Number of Warrants Outstanding, Weighted Average Exercise Price, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations Number of warrants outstanding, weighted average exercise price, expired Number of warrants outstanding, weighted average exercise price, expired [Default Label]